SCHEMBL1798403

SCHEMBL1798403

CCOc1ccccc1C1(OC(=O)N2CCN(C3CCN(C)CC3)CC2)C(=O)N(S(=O)(=O)c2ccc(C#N)cc2)c2ccc(Cl)cc21

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
AVPR1B P47901 4/20 0.39
PSEN1 P49768 8/20 0.38
PSEN2 P49810 8/20 0.38
APH1B Q8WW43 8/20 0.38
NCSTN Q92542 8/20 0.38
APH1A Q96BI3 8/20 0.38
PSENEN Q9NZ42 8/20 0.38
APP P05067 5/20 0.36
KMT2A Q03164 1/20 0.36
OXTR P30559 2/20 0.36
AVPR1A P37288 2/20 0.36
TRPV4 Q9HBA0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1796113 0.93 AVPR1B (0.39) KDM4EALDH1A1SMN1; SMN2AVPR1BPSEN1
SCHEMBL1795495 0.93 KDM4E (0.43) KDM4EALDH1A1SMN1; SMN2AVPR1BPSEN1
SCHEMBL1799057 0.92 AVPR1B (0.42) KDM4EALDH1A1SMN1; SMN2AVPR1B
SCHEMBL1795337 0.92 AVPR1B (0.42) KDM4EALDH1A1SMN1; SMN2AVPR1BPSEN1
SCHEMBL1795051 0.92 AVPR1B (0.42) KDM4EALDH1A1SMN1; SMN2AVPR1BKMT2A
SCHEMBL1799084 0.91 AVPR1B (0.42) KDM4EALDH1A1SMN1; SMN2AVPR1BPSEN1
SCHEMBL1795105 0.91 AVPR1B (0.41) KDM4EALDH1A1SMN1; SMN2AVPR1B
SCHEMBL1796847 0.91 AVPR1B (0.44) SMN1; SMN2AVPR1BKMT2A
SCHEMBL1796879 0.90 AVPR1B (0.49) KDM4EALDH1A1AVPR1B
Hydrochloric Acid SCHEMBL1794839 0.90 AVPR1B (0.44) KDM4EALDH1A1SMN1; SMN2AVPR1BPSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338590-B2 Substituted oxindole derivatives and medicaments containing the same ABBOTT GMBH & CO. KG (DE) 2012-12-25 US disclosed
US-20110257194-A1 SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME ABBOTT GMBH & CO. KG (DE) 2011-10-20 US disclosed
US-7951807-B2 Substituted oxindol derivatives and medicaments containing the same ABBOTT GMBH & CO. KG (DE) 2011-05-31 US disclosed
US-20090005397-A1 Substituted Oxindol Derivatives and Medicaments Containing the Same ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005397-A1 Substituted Oxindol Derivatives and Medicaments Containing the Same OXTR, AVPR2, AVPR1B KDM4E 4081/4885ALDH1A1 917/4885SMN1; SMN2 3412/4885
US-20110257194-A1 SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME OXTR, AVPR2, AVPR1B KDM4E 4261/4885ALDH1A1 814/4885SMN1; SMN2 3923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.